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Abstract
Background: Granulysin (GNLY) is produced by human lymphocyte subpopulations and exhibits antimicrobial
activity against Mycobacterium tuberculosis. We examined the association between GNLY levels in blood and latent
tuberculosis (TB) infection.
Methods: Latency of TB infection among Vietnamese healthcare workers was estimated using interferon-gamma
release assays (IGRA), and serum GNLY concentrations were measured using enzyme-linked immunosorbent assays.
The levels of GNLY expression in whole blood and the presence of GNLY alleles with the exon-4 polymorphism
rs11127 were also determined using PCR-based methods.
Results: Among 109 study participants, 41 (37.6 %) were IGRA positive and had significantly lower serum GNLY
concentrations compared with IGRA-negative participants (adjusted mean, 95 % confidence interval; 2.03, 1.72–2.44
vs. 2.48, 2.10–2.92 ng/ml, P = 0.0127; analysis of covariance). Serum GNLY concentrations and TB antigen-stimulated
interferon-gamma values were weakly inversely correlated (r = −0.20, P = 0.0333). Serum GNLY concentrations varied
with GNLY genotypes even after adjustment for gender and age (adjusted P = 0.0015) and were moderately correlated
with GNLY expression in blood cells (r = 0.40, P < 0.0001). In subsequent analyses, low serum GNLY concentrations
were significantly associated with IGRA status (adjusted odds ratio and 95 % confidence interval, 0.55 and 0.31–0.98,
respectively), although GNLY genotype and mRNA levels were not.
Conclusions: Decreased GNLY, presumably at the protein level, is linked to the immunological condition of latent
TB infection.
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Background
According to global estimation, latent Mycobacterium
tuberculosis (MTB) infection is present in approximately
one third of the human population (~2 billion people)
[1]. Latent infection follows prolonged survival of MTB
despite containment by host defense mechanisms [2]
and contributes significantly to the risk of overt disease
following reactivation of MTB under conditions of
compromised immunity [3], which presents a major
obstacle to achieving global tuberculosis (TB) control.
Interferon-gamma release assays (IGRA) are diagnostic
of TB infection and operate on the principle that MTB-
specific antigens provoke immune responses in whole
blood after the establishment of infection [4]. IGRA offer
more specific detection of latent TB infection (LTBI)
than tuberculin skin test in many circumstances [5].
Accordingly, QuantiFERON-TB Gold In-tube enzyme-
linked immunosorbent assay (ELISA)-based IGRA are
recommended in multiple current guidelines, including
those of the United States Center for Disease Control
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and Prevention for testing LTBI among people who are
at risk of TB infection (i.e., healthcare workers) [6].
As an effector molecule, the saposin family protein
granulysin (GNLY) is involved in protective immunity,
and is released from natural killer (NK) cells, NKT
cells, γδ T cells, and cytotoxic T lymphocytes (CTLs).
This molecule directly eliminates extracellular MTB
and intracellular bacteria in the presence of perforin
by causing osmotic shock and inducing apoptosis [7].
Recently Walch et al. [8] suggested that GNLY initially
penetrates infected cells and delivers bactericidal gran-
zymes to intracytoplasmic bacteria. Hence, in the presence
of GNLY, granzymes eliminate bacteria independently of
host cell death.
Precursor and mature GNLY proteins of 15 and 9 kDa,
respectively, have been identified, and mature GNLY is
found with perforin and granzymes in cytotoxic granules.
Moreover, a previous report has shown that the 9-kDa
mature protein is mainly secreted from activated CTLs,
whereas the 15-kDa precursor protein is found in plasma
under physiological conditions [9]. Although the precur-
sor protein may have more potent chemotactic and in-
flammatory activities, its physiological function remains
poorly understood [10].
Circulating GNLY levels may be a useful indicator of
overall host cellular immunity [11]. Moreover, GNLY
expression has been identified as a marker for outcomes
in cancer and organ transplantation patients and is an
important mediator of damage in skin diseases [10]. In
TB, plasma GNLY levels were significantly lower in
patients with active disease than in healthy individuals
and increased after successful anti-TB treatment [12].
In an animal study, GNLY expression was associated
with protection after vaccination against TB in cattle
[13]. However, it is not clear whether GNLY levels are
associated with human LTBI. In the present study, we
investigated the relationship between serum GNLY con-
centrations and LTBI status as diagnosed using IGRA,
determined GNLY mRNA expression in blood cells, and
analyzed GNLY genetic polymorphisms.
Methods
Study population and data collection
Healthcare workers were recruited from ten district TB-
centers in Hanoi city. These TB centers are responsible
for implementing directly observed treatment short-course
(DOTS) programs for half of the city’s population under
the management of a municipal TB hospital (Hanoi Lung
Hospital). Staff members who did not participate in the
2007 LTBI survey in this hospital [14] were also recruited
and those who were employed for less than one year
were excluded.
All study participants were interviewed and demo-
graphic information and factors associated with TB
exposure were recorded using a structured questionnaire.
Histories of Bacillus Calmette-Guérin (BCG) vaccination
were obtained and confirmed according to the presence of
BCG scars. Peripheral blood was collected for IGRA and
for analyses of serum concentrations, mRNA expression,
and polymorphisms of GNLY. Participants were encour-
aged to take chest X-rays and sputum tests, when IGRA
positive status was identified. The participants were also
given the chances of LTBI treatment after consultation
with TB specialists.
Interferon-gamma release assays
IGRA for TB are used to estimate interferon-gamma
induction by MTB-specific antigens (TB antigens). In
this study, ELISA-based IGRA were performed using the
third version assay QuantiFERON-TB Gold In-Tube™
(Cellestis, Victoria, Australia). Briefly, whole blood was
collected in separate tubes that were not pre-coated with
any stimulants for the negative control, and pre-coated
with mitogen for the positive control or TB antigens.
After 18 h incubation at 37 °C, concentrations of
interferon-gamma in plasma supernatants were mea-
sured using the ELISA method. Interferon-gamma con-
centrations were calculated by subtracting negative
control values from TB antigen-stimulated values, and
the cut-off value was 0.35 IU/ml. The testing procedure
was carefully monitored [15] and quality control was
included in each run according to the manufacturer’s
instructions.
Serum granulysin assays
Both 15- and 9-kDa forms of serum GNLY were mea-
sured using a sandwich ELISA system with anti-GNLY
(RB1) mouse IgG1κ as the capturing antibody and
anti-GNLY-biotin (RC8) mouse IgG1κ as the detecting
antibody as described previously [11]. Recombinant
human (rh)-GNLY was used as a standard and culture
supernatants from GNLY (15 kDa)-expressing Cos-7
cells were used as positive controls. GNLY concentra-
tions were calculated from a standard curve of serially
diluted rh-GNLY standards. This ELISA system is spe-
cific for GNLY and has a detection limit of approxi-
mately 20 pg/ml [11].
Quantitative real-time polymerase chain reaction (PCR) of
granulysin mRNA in whole blood
Whole blood samples of 2.5 ml were collected into PAX-
gene™ Blood RNA tubes (PreAnalytiX, Hombrechtikon,
Switzerland) and stored as recommended by the manu-
facturer. Total RNA was then extracted using PAXgene™
Blood RNA Kits (QIAGEN, Hilden, Germany) and
reverse transcribed using random nonamers (TaKaRa,
Shiga, Japan) and SuperScript III reverse transcriptase
(Invitrogen, Carlsbad, CA, USA). Quantitative PCR was
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performed using the TaqMan® Gene Expression Assay
Hs00246266_m1 for GNLY (Applied Biosystems, Foster
City, CA, USA) with a CFX96 real-time PCR system
(BioRad, Hercules, CA, USA). GNLY expression was
normalized to that of GAPDH using the ΔΔCt method
[16] and mRNA expression levels of GNLY were
expressed relative to control cDNA.
Single nucleotide polymorphism analysis
Genomic DNA samples were extracted from blood cells
using QIAamp DNA Blood Mini Kits (QIAGEN) and
were subjected to PCR amplification for analysis of
single nucleotide polymorphism (SNP) of the GNLY.
Among the Kinh Vietnamese people, using the 1000
Genomes Database, twenty-one SNPs were identified in
GNLY and the 5′ region up to 1000 bp from the tran-
scription start site of the reference mRNA sequence
(NM_006433.4) [17]. All SNPs were in strong linkage
disequilibrium (D’ = 1, r2 > 0.85) with each other, except
for the SNP rs2043760 in intron 1 (D’ = 1, r2 = 0.7). A
non-synonymous SNP rs11127 (C/T) of the exon 4
(NM_006433.4) was selected and genotyped as a repre-
sentative SNP. Genomic DNA was amplified using the
primers 5′-GGAGGTATCAGTCTAGAGGTA-3′ and
5′-GCTAAAGTCCATCTGCTCAA-3′, and a mismatch
nucleotide (bold) was introduced in the sense primer to
generate a Kpn I restriction enzyme site when the
rs11127 allele was C. Genotype was determined ac-
cording to the length of PCR products after digestion
with Kpn I (TaKaRa) and C and T alleles gave 207- and
229-bp fragments, respectively.
Statistical analysis
Proportions between two study groups were compared
using the chi-squared test. First, the serum GNLY con-
centrations measured by ELISA were used to check
their distribution, and Wilcoxon rank-sum test was
used to compare the distribution between groups.
Then serum GNLY concentrations and GNLY mRNA
levels were used for further analyses after logarithmic
transformation of the values to approximate normal
distribution. Since GNLY levels are influenced by
gender and age, measurements of GNLY in the two
groups were compared using analysis of covariance
(ANCOVA) to adjust for covariates after performing
unpaired t-tests. Relationships between GNLY levels
and other parameters were assessed using Pearson’s
correlation coefficients and logistic regression models
were used to assess risk factors for positive IGRA sta-
tus. Allele-number dependent changes in gene expres-
sion were identified using univariate and multivariate
linear regression models. Variables with biological
meaning and with P values < 0.2 in univariate analyses
were included in multivariate models. Differences and
correlations were considered significant when P < 0.05,
unless otherwise specified. Statistical analyses were
performed using STATA version 11 (StataCorp, College
Station, TX, USA).
Results
Characteristics of the study population
Among 109 healthcare workers, 53 (46.8 %) were recruited
from the 225 staff members working in a municipal
hospital that specializes in TB, and 150 of these mem-
bers participated in the 2007 TB infection survey. This
hospital has 260 inpatient beds, receives approximately
5000 inpatients per year, performs 120 consultation per
day in the hospital outpatient department, and per-
forms 7000 examinations per year in the community. In
addition, 56 (51.4 %) healthcare workers were recruited
from TB units that are located in district centers of pre-
ventive medicine, which function to implement DOTS
at the grass roots level.
All participants answered questionnaires and provided
blood samples. No participants showed physical signs of
active TB. Almost half of the participants were less than
30 years old and 76.2 % of participants were female.
Approximately 10 % of participants were obese with a
body mass index (BMI) ≥ 25.0 and 50 % of participants
had histories of BCG vaccination, as indicated by the
presence of BCG scars. Although 78.0 % of participants
declared frequent exposure to TB in their working
places, only 42 (38.5 %) wore masks frequently (Table 1).
Serum granulysin levels and interferon-gamma levels
after stimulation
Forty-one individuals were IGRA positive (37.6 %; 28.5–
47.4 %). IGRA-positive status did not differ significantly
between subjects from the TB hospital and district TB
centers (data not shown). Distribution of GNLY levels
was significantly different between IGRA-positive and
negative groups (median, interquartile range; 2.14, 1.70–
2.82 vs. 2.60, 2.01–3.23 ng/ml, P = 0.0190 by Wilcoxon
rank-sum test) (Fig. 1). After logarithmic transformation
of GNLY values and adjustment for age and gender
using ANCOVA, GNLY concentrations were significantly
lower in the IGRA-positive group than in the IGRA-
negative group (adjusted mean, 95 % confidence inter-
vals (95 % CI); 2.03, 1.72–2.44 vs. 2.48, 2.10–2.92 ng/ml;
P = 0.0127; Table 2). Moreover, GNLY concentrations
were negatively correlated with interferon-gamma levels
after stimulation with the TB antigens used in IGRA
(r = −0.20, P = 0.0333; Fig. 2).
The levels of TB exposure assessed by the question-
naire [14] were not different between IGRA-positive and
negative groups (data not shown).
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Serum granulysin concentrations, granulysin mRNA
expression levels in blood, and polymorphisms of
rs11127 SNP in exon 4 of the granulysin gene
A positive correlation was identified between serum GNLY
concentrations and GNLY mRNA expression levels in
the blood (r = 0.40, P < 0.0001; table not shown). In the











< 18.5 7 6.4
18.5–24.9 92 84.4
≥ 25.0 10 9.2
Education level
High school 3 2.8
Primary, secondary, pre-university 76 69.7






Ever diagnosed as TB
No 107 98.2
Yes 2 1.8
Ever treated for TB
No 107 98.2
Yes 2 1.8
Years served in healthcare profession
< 2 26 23.9
2–4.99 37 33.9
5–9.99 21 19.3
≥ 10 25 22.9
Job
Medical doctor 19 17.4
Nurse 55 50.5
Laboratory Technician 11 10.1
X-ray technician 2 1.8
Other 22 20.2
Current working place
Lung hospital 53 48.6
District TB center 56 51.4
Current working area
Outpatient department 9 8.3
TB ward 57 52.3
















l P* = 0.0190
Fig. 1 Distribution of serum GNLY concentrations in IGRA-negative
and IGRA-positive groups. Blue horizontal lines (+++), median values;
green line (—), interquartile range; *by Wilcoxon rank-sum test;
GNLY, granulysin; IGRA, Interferon-gamma release assays
Table 1 Characteristics of the study population (n = 109)
(Continued)
Non-TB ward 11 10.1
TB bacteriology laboratory 11 10.1
Non-TB bacteriology laboratory 1 0.9
















TB tuberculosis, NA not available, BCG Bacillus Calmette–Guérin
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subgroup analysis, serum GNLY concentrations correlated
with GNLY mRNA, as the number of C allele was
increased (r = 0.24, P = 0.1057 for TT genotype; r = 0.44,
P = 0.0012 for CT; and r = 0.80, P = 0.001 for CC; Fig. 3).
Serum GNLY levels varied significantly with genotype
after adjustment for gender and age (P = 0.0015) and
were low in participants with the CC genotype (adjusted
mean, 95 % CI; 1.60, 1.25–2.05 ng/ml), intermediate in
participants with the CT genotype (2.23, 1.8–2.64), and
high in participants with the TT genotype (2.48, 2.12–
2.92). Moreover, numbers of C alleles in these individuals
were inversely associated with serum GNLY levels in
univariate and multivariate regression models (Table 3).
However, no clear differences in mRNA expression
were found between participants with CC, CT, and TT
genotypes either before or after adjustment for gender
and age (adjusted mean, 95 % CI; 9.21, 6.11–13.87;
12.43, 9.30–16.61; and 9.78, 7.46–12.68 arbitrary units,
respectively; P = 0.0994). Moreover, univariate and
multivariate regression models did not show any signi-
fication associations between numbers of C alleles and
GNLY mRNA expression levels (Table 3).
Factors associated with latent tuberculosis infection
estimated using interferon-gamma release assays
In both univariate and multivariate regression models,
significant reverse associations were shown between
IGRA-positive status and serum GNLY concentrations
[unadjusted odds ratio (OR), 95 % CI; 0.55, 0.35–0.89;
and adjusted OR, 95 % CI; 0.55, 0.31–0.98], whereas the
number of C alleles and GNLY mRNA levels were not
associated with IGRA-positive status. High BMI was
independently associated with IGRA-positive status
(Table 4). In addition, GNLY concentrations were sig-
nificantly lower in IGRA-positive group than in IGRA-
negative group, even after the effect of C alleles was
considered (ANCOVA; P = 0.006, data not shown).
Discussion
In the present study, we investigated GNLY in LTBI as
identified using IGRA among healthcare workers in
Hanoi, Vietnam. Serum GNLY concentrations in the
IGRA-positive group were significantly lower than those
in the IGRA-negative group. Moreover, serum GNLY
concentrations were significantly positively correlated
with GNLY mRNA expression levels in blood and were
dependent on the number of C alleles of the rs11127
SNP in exon 4 of GNLY, whereas GNLY mRNA expres-
sion levels were not dependent on the number of C
alleles of the rs11127 SNP in exon 4 of GNLY. Of the
three parameters (SNP genotype, mRNA expression, and
concentrations of GNLY in blood), only circulating levels
of GNLY protein were significantly negatively associated
with IGRA-positive status.
GNLY, a major antimicrobial molecule, has been shown
to preferentially bind and disrupt cholesterol-poor mem-
branes of microbes [10]. However, no homolog has been
found in rodents, and investigations using human samples
are required to elucidate the significance of GNLY in vivo,
as shown in the present study. In a recent study [8], bac-
tericidal mechanisms involving cooperation of GLNY and
granzymes have been clarified. Specifically, GLNY delivers
granzymes to intracellular bacteria leading to oxidative
damage through cleavage of bacterial antioxidants. Thus,
Table 2 GNLY concentrations and IGRA results
IGRA negative IGRA positive
(n = 68) (n = 41)
Before adjustmenta
Mean valueb of GNLY concentrations 2.53 2.10
95 % CI 2.32–2.77 1.84–2.36
P valuec 0.0116
After adjustmenta
Mean valueb of GNLY concentrations 2.48 2.03
95 % CI 2.10–2.92 1.72–2.44
P valued 0.0127
GNLY granulysin, IGRA interferon-gamma release assays, 95 % CI 95 %
confidence intervals
aadjustment for age and sex
bGNLY concentrations with the original unit (ng/ml) are shown after
transforming back
cunpaired t-test after logarithmic transformation of GNLY concentrations
dANCOVA after logarithmic transformation of GNLY concentrations
r = -0.20
(P = 0.0333)


































Fig. 2 Serum GNLY concentrations and interferon-gamma levels
after stimulation with the TB antigens in IGRA. GNLY, granulysin;
TB-Ag-stimulated interferon-gamma values, tuberculosis antigen
values minus negative-control values in the blood. The scales of
x- and y- axes are based on the values after logarithmic transformation
of the original units; IU/ml for IGRA values and ng/ml for serum
GNLY concentrations
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GNLY shows both cytolytic and bactericidal activities
with other effector molecules such as granzymes and
perforin, although GNLY acts independently at micro-
molar concentrations and under hypotonic or acidic
conditions [18, 19].
Since CTLs play crucial roles in the containment of
MTB in TB granulomas [2, 19], GNLY appears to be an
important effector molecule in human TB infection,
alone and in cooperation with granzymes and perforin.
In a previous study in which the same ELISA system
was used [11], GNLY concentrations of 244 presumably
TB-unexposed healthy Japanese individuals were 3.7 ± 3.2
ng/ml (mean ± standard deviation), and these values were
even higher than those in IGRA-negative Vietnamese indi-
viduals presumably resistant to TB infection in our study.
It suggests that TB exposure may decrease serum GNLY
levels, and that LTBI state may further suppress the level
by some unknown mechanism, though effects of ethnicity
and other background such as comorbidity and nutritional
status should be taken into consideration and it is difficult
to draw any conclusions from direct comparison between
different studies. Moreover, previous studies of active
TB disease have shown that GNLY levels in the blood
vary with clinical stage [12, 20]. Although serum GNLY
concentrations were lower in the LTBI group than in
the non-LTBI group, this GNLY concentration (median,
interquartile range; 2.144, 1.703–2.824 ng/ml) was higher
than that shown previously in newly diagnosed active
TB (median ± standard error, 1.511 ± 0.287 ng/ml) and
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Fig. 3 Serum GNLY concentrations and GNLY mRNA gene expression levels in the blood by different genotypes of rs11127 SNP of the exon 4 of
GNLY gene. GNLY, granulysin; mRNA, messenger RNA; SNP: single nucleotide polymorphism. The scales of x- and y- axes are based on the values
after logarithmic transformation of the original units; arbitrary unit for GNLY mRNA levels, and ng/ml for serum GNLY concentrations
Table 3 GNLY polymorphisms and other factors associated with serum GNLY concentrations or GNLY mRNA expression levels in
blood in univariate and multivariate regression models (n = 109)
Univariate Multivariate
Coefficient 95 % CI P value Coefficient 95 % CI P value
a) Polymorphism of rs11127 SNP in exon 4 of the GNLY was inversely associated with serum GNLY concentrations (log-transformed values)
Age (increased by one year) 0.00 −0.01 to 0.01 0.985 0.00 −0.01 to 0.01 0.666
Gender (female vs. male) 0.04 −0.13 to 0.22 0.628 0.08 −0.09 to 0.25 0.359
Genotype (increased by one C allele) −0.18 −0.29 to −0.07 0.001 −0.19 −0.30 to −0.08 0.001
b) Polymorphism of rs11127 SNP in exon 4 of the GNLY was not associated with GNLY mRNA expression levels (log-transformed values) in blood
Age (increased by one year) 0.00 −0.01 to 0.01 0.870 0.00 −0.01 to 0.01 0.883
Gender (female vs. male) −0.33 −0.61 to −0.05 0.021 −0.34 −0.62 to −0.06 0.019
Genotype (increased by one C allele) 0.03 −0.15 to 0.21 0.725 0.06 −0.12 to 0.24 0.532
GNLY granulysin, SNP single nucleotide polymorphism, 95 % CI 95 % confidence interval
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collaborative study using the same ELISA system [20].
Potential interpretations of low GNLY levels in TB infec-
tion are as follows. First, the present data may reflect
sequestration of GNLY-producing cells: Lymphocytes with
high GNLY expression accumulate at the sites of latent in-
fection. At these sites, continuous cross-talk between the
host immune system and the pathogen [21] may facilitate
GNLY turnover, and accumulation of these GNLY-
producing lymphocytes potentially results in a relative
decrease in circulating GNLY in infected individuals.
Moreover, it is well known that MTB-specific CTLs
accumulate in areas surrounding infected epithelioid
cells of TB granulomas [19, 22] and may also occur in
individuals with LTBI. This condition may differ from
that of chronic TB, which is characterized by persistent
inflammation and active clinical manifestations, and is
associated with diminished GNLY in granuloma-
associated CTLs, resulting in impaired CTL activities
[23]. Second, protein levels of GNLY were negatively as-
sociated with interferon gamma release in the present
study, whereas GNLY expression levels and GNLY poly-
morphisms were not, suggesting that GNLY may lack
stability in TB infection, and its rates of metabolism or
degradation may be affected by chronic inflammation
and immune reactions in TB. Finally, during the very
early stages of TB infection, NK and NKT cells may des-
troy pathogens and infected cells [24], and as innate and
intermediate immune cells, they express both GNLY and
granzymes. Hence, limited expression of GNLY in these
cells may lead to failure to eliminate MTB and it may
cause IGRA-positive status. However, although frequen-
cies of the C allele of the rs11127 GNLY polymorphism
may lead to low serum GNLY concentrations, these
inherent genotypes were not associated with IGRA-
positive status, indicating that low GNLY concentrations
may be a consequence rather than a cause of LTBI.
Sputum smear-positive cases of TB have long been
targeted in TB control programs [25] and preventive
therapy for LTBI in the general population has not been
feasible in most countries with high TB burdens, in-
cluding in Vietnam. However, identification of sub-
groups of individuals who are at high risk of developing
active disease may provide a useful and cost-effective
strategy to control TB [26]. Thus, future investigations
are required to explore the roles of GNLY and other
antimicrobial molecules as biomarkers, for example, in
prospective cohort studies with follow up of blood
levels during the first two years after infection.
Table 4 Serum GNLY concentrations and other factors associated with IGRA-positive status in univariate and multivariate logistic
regression models (n = 109)
No (%) Univariate Multivariatea
OR 95 % CI OR 95 % CI
Age (by year) 1.02 0.98–1.06 1.03 0.98–1.09
Sex
Male 11/26 (42.3) Reference Reference
Female 30/83 (36.1) 0.77 0.31–1.89 0.83 0.26–2.65
BMI
18.5–24.9 31/92 (33.7) Reference Reference
< 18.5 3/7 (42.9) 1.48 0.31–7.01 3.99 0.53–29.92
≥ 25.0 7/10 (70.0) 4.59 1.11–18.99 8.43 1.37–51.75
Job
Others 4/22 (18.2) Reference Reference
Doctor 10/19 (52.6) 5.00 1.22–20.46 3.37 0.69–16.52
Nurse 22/55 (40.0) 3.00 0.89–10.06 2.51 0.56–11.18
Technician 5/13 (38.5) 2.81 0.59–13.34 1.48 0.22–10.03
Working place
Non-TB 8/30 (26.7) Reference Reference
TB 32/77 (41.6) 1.96 0.77–4.94 1.70 0.55–5.22
GNLY concentration (by ng/ml) 0.55 0.35–0.89 0.55 0.31–0.98
GNLY mRNA expression (by one unit) 0.95 0.88–1.02 0.98 0.88–1.08
Genotype (by number of C allele) 0.84 0.47–1.51 - -
GNLY granulysin, IGRA interferon-gamma release assays, OR odds ratio, 95 % CI 95 % confidence interval, BMI body mass index, TB tuberculosis; significant associations
are presented in bold
aMultivariate analyses included age, sex, BMI, job category, working place, GNLY concentration, and GNLY mRNA expression levels
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Our study has some limitations. We could not recruit
individuals with no TB exposure. We compared our
results with those obtained from previous studies and
discussed possible interpretations of our findings. Be-
cause previous studies of granzymes [8] and perforin
[7] reveal that GNLY works in cooperation with these
molecules to eliminate MTB, it may be of further value
to investigate the co-localization of these effector mole-
cules using flow cytometry or cell population analyzers
to offer greater certainty of this assertion. Moreover,
the 15-kDa precursor form of GNLY is better known as
a potent chemotactic factor during inflammation than
as a bactericidal molecule. Since the present sandwich
ELISA system captures both forms of GNLY, further
studies are required to determine which form of GNLY
is predominant in blood from patients with LTBI and
active TB. Lastly, the SNP rs11127 (C/T) of exon 4
leads to an amino acid substitution (Ile104Thr) in the
GNLY protein and may accelerate consumption or en-
hance stability of GNLY. Since GNLY genotype was as-
sociated with GNLY concentration, but not with mRNA
expression level, we can assume that GNLY polymorphism
may have affected GNLY concentrations at the protein
level; and GNLY may have been expressed in the way
partly independent of GNLY genotype. A genetic vari-
ation that directly affects GNLY concentrations was not
clearly determined in this study because of strong link-
age disequilibrium around the GNLY locus. Neverthe-
less, the SNP rs11127 has been reported to have an
important role in clearance of hepatitis B virus [27, 28],
and further study on GNLY genetic polymorphism is
necessary whether it may contribute to optimize granu-
lysin vaccines against TB [29, 30].
Conclusion
Serum GNLY concentrations in IGRA-positive partici-
pants were significantly lower than in those with IGRA-
negative status. Therefore, changes in circulating GNLY,
presumably at the protein level, may be involved in the
immunological condition of LTBI.
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